...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diagnostic microbiology and infectious disease >Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates.
【24h】

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates.

机译：加替沙星对空肠弯曲杆菌（包括耐氟喹诺酮的临床分离株）的比较抗菌活性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Campylobacter jejuni is an important pathogen that causes gastroenteritis, as well as other disease states such as meningitis and septic arthritis. In this study, the Etest (AB BIODISK, Solna, Sweden) results were compared to a reference agar dilution method using gatifloxacin, a new 8-methoxyfluoroquinolone. A total of 53 strains of C. jejuni initially isolated from patients in California and Mexico were tested. Results demonstrated a high correlation (r = 0.88) between the two utilized in vitro dilution methods. In addition, gatifloxacin activity was compared to that of ciprofloxacin, metronidazole, amoxicillin, erythromycin, chloramphenicol, gentamicin, tetracycline, and trimethoprim/sulfamethoxazole using the Etest. Gatifloxacin (MIC90, 4 micrograms/ml) was approximately eight- to 16-fold more potent than ciprofloxacin (Mic90, > 32 micrograms/ml), a commonly used fluoroquinolone for Campylobacter infections. Eight strains highly resistant to ciprofloxacin (MIC90, > 32 micrograms/ml) were tested for cross resistance against the newer fluoroquinolones (gatifloxacin, levofloxacin, trovafloxacin) and the rank order of potency was: gatifloxacin (MIC50, 16 micrograms/ml) > trovafloxacin = levofloxacin (MIC50, > 32 micrograms/mL). However, only 25% ciprofloxacin-resistant strains were inhibited by < or = 1 microgram/mL of gatifloxacin or trovafloxacin. These results for gatifloxacin against C. jejuni strains must be further assessed in the context of in vivo trials before the clinical role of this new fluoroquinolone can be determined. The Etest appears to be a simple and precise susceptibility test method for testing C. jejuni isolates against fluoroquinolones and other alternative therapeutic agents.
机译：空肠弯曲杆菌是引起肠胃炎以及其他疾病如脑膜炎和败血性关节炎的重要病原体。在这项研究中，将Etest（AB BIODISK，瑞典索尔纳，瑞典）的结果与使用新的8-甲氧基氟喹诺酮加替沙星的参考琼脂稀释方法进行了比较。测试了最初从加利福尼亚和墨西哥患者中分离出的总共53株空肠弯曲杆菌菌株。结果表明两种体外稀释方法之间具有高度相关性（r = 0.88）。此外，使用Etest将加替沙星活性与环丙沙星，甲硝唑，阿莫西林，红霉素，氯霉素，庆大霉素，四环素和甲氧苄氨嘧啶/磺胺甲基异恶唑的活性进行了比较。加替沙星（MIC90，4微克/毫升）的效力比环丙沙星（Mic90，> 32微克/毫升）（弯曲杆菌感染常用的氟喹诺酮）的效价高约8至16倍。测试了八种对环丙沙星具有高度抗药性的菌株（MIC90，> 32微克/毫升）对新型氟喹诺酮类药物（加替沙星，左氧氟沙星，曲伐沙星）的交叉耐药性，效价等级为：加替沙星（MIC50，16微克/毫升）>曲妥沙星=左氧氟沙星（MIC50，> 32微克/毫升）。然而，加替沙星或Trovafloxacin≤1微克/ mL只能抑制25％的环丙沙星耐药菌株。加替沙星抗空肠弯曲杆菌菌株的这些结果必须在体内试验的背景下进一步评估，然后才能确定这种新的氟喹诺酮的临床作用。 Etest似乎是一种简单而精确的药敏试验方法，用于测试空肠弯曲杆菌分离株对氟喹诺酮类药物和其他替代治疗剂的敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号